. Author manuscript; available in PMC: 2014 Sep 26.

Published in final edited form as: J Clin Pharmacol. 2013 Mar 28;53(5):491–504. doi: 10.1002/jcph.73

Table 5.

Multivariate Cox Proportional Hazards Analysis of Progression-Free and Overall Survival

	PFS				OS
Covariates	Parameter estimate^a	SE^b	HR (95% CI)	P^c	Parameter estimate^a	SE^b	HR (95% CI)	P^c
Gender	0.542	0.211	1.72 (1.14, 2.60)	.010	—	—	—	—
Prior therapy	0.472	0.221	1.60 (1.04, 2.47)	.033	0.751	0.232	2.12 (1.35, 3.34)	.001
ECOG PS	0.598	0.225	1.82 (1.17, 2.83)	.008	0.861	0.231	2.37 (1.50, 3.72)	<.001
Hemoglobin, g/dL	−0.509	0.217	0.601 (0.393, 0.921)	.019	−1.06	0.249	0.348 (0.213, 0.567)	<.001
AUC, hxng/mL^d,^e	−0.0956	0.0453	0.909 (0.832, 0.993)	.035	−0.145	0.0574	0.866 (0.773, 0.968)	.012
dBP, mm Hg^e,^f	−0.416	0.122	0.660 (0.519, 0.839)	<.001	−0.303	0.118	0.739 (0.586, 0.931)	.010

AUC, area under the plasma concentration–time curve; CI, confidence interval; dBP, diastolic blood pressure; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; SE, standard error.

Regression coefficient.

Standard error of regression coefficient.

Based on log-rank (score) test at significance in multivariate model. Backward elimination of covariates was performed at significance level of P = .05 using the log-likelihood ratio test.

Hazard ratio per 100 hxng/mL increase of AUC.

Final estimates after adjusting baseline hazard ratios with prognostic factors (gender, prior therapy, ECOG PS, and hemoglobin).

Hazard ratio per 10 mm Hg increase of dBP.